Dr. Ma Qian was invited to present the latest research at the European Society of Cardiology (ESC) Congress

European Society of Cardiology (hereinafter referred to as ESC) Congress 2023 was held from August 25-28 at RAI International Exhibition and Congress Centre in Amsterdam, the Netherlands. ESC Congress is one of the world’s largest and the most influential cardiovascular academic events and the 2023 Congress has been developed around “joining forces to protect the heart”. As an ESC professional member, Dr. Ma Qian, Chairman and CEO of Beijing Inno Medicine Co., Ltd., was invited as a keynote speaker at the 2023 Congress. Dr. Ma Qian joined over 30,000 experts and scholars from 100+ countries to explore cutting-edge technological innovations in cardiovascular research and presented the latest advancements in cardiovascular drug development of Inno Medicine. 

In the session of drug-related risk management in chronic coronary syndromes, Dr. Ma Qian delivered a keynote speech titled “Non-clinical evaluation of YN001 promising drug for atherosclerotic therapy by targeted delivery system”, sharing non-clinical study data and updates on the FDA filing progress of YN001. The speech served as a platform for academic exchange with fellow experts and scholars in attendance. 

Dr. Ma Qian demonstrated that the plaque regression rate of YN001, an actively targeted liposome drug, was as high as 55% in the mouse model of atherosclerosis, and provided a comprehensive explanation of the drug’s mechanism of action and safety studies. YN001 has successfully obtained IND approval from the US FDA. This marks a significant milestone as YN001 becomes the pioneering cardiovascular drug to receive accelerated approval from the FDA based on alternative clinical trial endpoints, with the data from the phase II clinical trials as the basis for FDA approval, accelerating the approval process.

During the discussion with the Chairperson of the session about YN001 R&D technology, Dr. Ma introduced that Inno Medicine holds the proprietary IPR of this targeted nano-drug delivery system. This technology employs targeted liposomal drug delivery to enhance drug safety and efficacy to accelerate and empower the R&D process for YN001 finally.

Following the meeting, Dr. Ma Qian discussed with Prof. Akiko Maehara (Director of the Intravascular Imaging Core Lab at CRF, USA), Prof. Patrick W. Serruys (Professor in Interventional Cardiology at NUIG, Medical Director of CORRIB Core Lab) and Prof. Yoshi Onuma (Medical Director of CORRIB Core Lab of Coronary Imaging). Prof. Maehara is highly respected for her expertise in intravascular imaging and physiology. Prof. Serruys is widely recognized as a pioneer in the field of coronary intervention therapy and has been honored with Lifetime Achievement Award from American College of Cardiology (ACC). He has successively served as a professor of interventional cardiology at Erasmus University and the University of Amsterdam. Prof. Onuma is an experienced expert in noninvasive and invasive coronary artery imaging.

Photo of Dr. Ma Qian and CORRIB Core Lab (Prof. Serruys: first on the right; Prof. Onuma: first on the left)

YN001’s rigorous research data, solid preclinical trial accumulation and favorable non-clinical efficacy were highly commended by the international community. Experts have praised the progress of YN001 in obtaining IND approval from the FDA and are willing to discuss cooperation on upcoming clinical studies.

Inno Medicine aims to enhance its collaboration with leading international scientific research teams during the ESC Congress. The company plans to expedite the introduction of its R&D products to the global market, focusing on addressing unmet clinical needs in the cardiovascular and cerebrovascular areas.

About Inno Medcine

Founded in 2016, Beijing Inno Medicine Co., Ltd. is a national high-tech enterprise. The company is committed to the discovery, development, and manufacturing of novel drugs. Our Chinese name “Yin Nuo” reveals our cultural values of benevolence and unwavering dedication to perfection. The company’s founder, Dr. Ma Qian, has extensive experience in clinical cardiology. Relying on the company’s in-house R&D center and its manufacturing facilities, she led the team to develop a targeted nano-drug delivery platform, which serves as foundation for establishing multiple product pipelines aimed at addressing the pressing unmet medical needs related to atherosclerosis, brain glioma, and more. Among our products, IND submission of YN001 was simultaneously made in China and in the US, and approval was granted by the FDA, making YN001 the world’s first targeted drug in cardiology to have gained clearance for clinical study. Currently a clinical study is being conducted in Australia.